Paladin Labs Announces the Canadian Launch of Travelan®

 MONTREAL, Aug. 5, 2014 /CNW/ -- Paladin Labs Inc., a subsidiary of Endo  International plc   (NASDAQ: ENDP) (TSX: ENL), announced today the launch of  Travelan®, a unique over-the-counter product to help reduce the risk of  travellers' diarrhea.  Travelan® is clinically proven to provide protection against the main cause  of travellers' diarrhea in 90% of consumers who use it(1). Travelan® is a  convenient option for all those travelling to at-risk regions such as Central  and South America, Mexico, Africa, the Middle East and Asia. It does not  require a prescription, and is not associated with any significant side  effects.  It is estimated that there are over 5 million trips made by Canadians to  at-risk regions every year(2). One-in-three Canadian vacationers have  experienced, or have travelled with someone who has experienced, travellers'  diarrhea(3). Sources of Enterotoxigenic Escherichia Coli (ETEC) bacteria,  which cause the majority of cases of travellers' diarrhea(4), can include  poorly cooked meat, contaminated raw vegetables or unpasteurized dairy  products. Given that no food group can be regarded as "safe"(4), research  demonstrates that three-quarters of Canadians have indicated that they would  take a preventive for travellers' diarrhea(3).  "We are pleased to announce the launch of Travelan® in Canada," said Mark  Beaudet, President of Paladin Labs Inc. "This option responds to the clear  market need for a clinically proven, accessible option to help reduce the risk  of travellers' diarrhea."  Paladin obtained the exclusive rights to market and sell Travelan(® )in  Canada, Latin America (including Brazil and Mexico) and Sub-Saharan Africa  (including South Africa) from Immuron Ltd (ASX:IMC) in November 2011.  About Travelan(®)  Travelan(®) is a natural product which is specifically designed to reduce the  risk of infection by ETEC, the most common cause of travellers' diarrhea. In  clinical trials, Travelan(®) showed efficacy of up to 90% in protecting  against infection with the type of E.Coli that causes travellers' diarrhea. In  addition, trials showed a significant reduction in abdominal cramps and  stomach pain compared to those who did not receive Travelan(®). There were no  reported treatment-related side effects in the clinical trials.  For more information, please visit www.travelancanada.ca  Suggested retail price: $29.99-39.99 (pack of 30 tablets).  Available on pharmacy shelves.  About Paladin Labs Inc.  Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty  pharmaceutical company focused on acquiring or in-licensing innovative  pharmaceutical products for the Canadian market. Paladin has a focused  marketing and sales organization that has helped it evolve into one of  Canada's leading specialty pharmaceutical companies. Paladin is an operating  company of Endo International plc (NASDAQ: ENDP) (TSX: ENL), a global  specialty healthcare company focused on improving patients' lives while  creating shareholder value.  Learn more at www.endo.com.  References  (1 )Travelan Product Packaging, 2013.  (2 )Statistics Canada, International Travel 2010, Catalogue no. 66-201-X.  (3 )Leger Marketing, State of Vacation:  Canadians Perspectives on Travellers'  Diarrhea, October 2011.  (4 )Public Health Agency of Canada, Canada Communicable Disease Report:  Statement on Travellers' Diarrhea, 15 March 2001.  Forward-Looking Statements  Cautionary Note Regarding Forward-Looking Statements  This press release contains forward-looking statements within the meaning of  the Private Securities Litigation Reform Act of 1995 and Canadian securities  legislation. Statements including words such as "believes," "expects,"  "anticipates," "intends," "estimates," "plan," "will," "may," "look forward,"  "intend," "guidance," "future" or similar expressions are forward-looking  statements. Because these statements reflect Endo's current views,  expectations and beliefs concerning future events, these forward-looking  statements involve risks and uncertainties. Although Endo believe that these  forward-looking statements and information are based upon reasonable  assumptions and expectations, readers should not place undue reliance on them,  or any other forward-looking statements or information in this news release.  Investors should note that many factors, as more fully described in the  documents filed by Endo and Endo Health Solutions Inc. ("EHSI") with  securities regulators in the United States and Canada including under the  caption "Risk Factors" in EHSI's Form 10-K, and Endo's Form 10-Q and Form 8-K  filings, as applicable, with the Securities and Exchange Commission and by  Endo with securities regulators in Canada on the System for Electronic  Document Analysis and Retrieval ("SEDAR") and as otherwise enumerated herein  or therein, could affect Endo's future financial results and could cause  Endo's actual results to differ materially from those expressed in  forward-looking statements contained in EHSI's Annual Report on Form 10-K. The  forward-looking statements in this press release are qualified by these risk  factors. These are factors that, individually or in the aggregate, could cause  Endo's actual results to differ materially from expected and historical  results. Endo does not assume any obligation to publicly update any  forward-looking statements, whether as a result of new information, future  developments or otherwise, except as may be required under applicable  securities law.    SOURCE  Endo International plc  Investors/Media: Blaine Davis, +353-1-669-6635, (484) 216-7158; Investors:  Jonathan Neely, (484) 216-6645; Media: Heather Zoumas-Lubeski, (484) 216-6829  CO: Paladin Labs Inc. ST: Canada NI: HEA MTC BTC NP  
Press spacebar to pause and continue. Press esc to stop.